Antiretroviral Drugs—PEP, PrEP and Treatment as Prevention

Researchers are exploring three ways to use HIV drugs to prevent HIV transmission:

	Post-exposure prophylaxis (PEP): PEP involves taking a short course of ARV drugs, usually for a month, after a high-risk exposure. Though experts believe that PEP works, based on large amounts of data in health care workers who were exposed to infected blood, it is not possible to ethically test this in humans for sexual exposure. To be most effective, PEP should be started immediately after possible exposure, waiting no more than 72 hours. If you suspect a high-risk exposure to HIV—semen leaking out of a condom during intercourse with an HIV-positive insertive partner; receptive anal sex without a condom with a partner who is either HIV positive or whose status you do not know or you have shared drug-injection works with someone who is either HIV positive or whose status you do not know—contact your health care provider or local hospital emergency room as soon as possible.
	Pre-exposure prophylaxis (PrEP): PrEP involves having an uninfected person take ARV drugs—usually Viread (tenofovir) or Truvada (tenofovir plus emtricitabine)—before, during and after possible high-risk exposures to reduce the risk of becoming infected. The earliest PrEP studies call for taking either Viread or Truvada every day, even during periods of minimal or low-risk sexual activity. Future studies may explore intermittent dosing strategies (e.g., using PrEP only during periods of high-risk sexual or drug-using activity). It is important to note that results from the initial PrEP trials will not be available before the fall of 2010, and no one is currently recommending that people attempt this strategy on their own.
	Treatment-as-prevention: In 2009, a Swiss medical committee issued a statement concluding that if an HIV-positive person's viral load is undetectable for at least six months while using ARV therapy, the risk of transmitting this virus to an HIV-negative partner is essentially nil (both partners also need to be free of other sexually transmitted diseases). This statement has been controversial, as the studies referenced in the statement primarily involved heterosexual couples in long-term monogamous relationships and do not account for the variables in real-world situations (e.g., HIV-positive individuals with multiple partners, individuals engaging in unprotected anal sex, people on ARV treatment with drug resistance and detectable viral loads, etc.). Though the risk may not necessarily be zero, experts agree that an HIV-positive person with an undetectable viral load is significantly less likely to transmit his or her virus to an HIV-negative partner. This understanding has prompted additional research to explore not only the personal benefits of treatment—AIDS-free survival for the person infected with HIV—but also the public health implications of getting all HIV-positive people, especially those who are unaware of their status, in to care and on treatment to reduce the ongoing spread of HIV.

Search for news stories about this topic